314 related articles for article (PubMed ID: 17060517)
1. Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis.
Thiel MA; Zinkernagel AS; Burhenne J; Kaufmann C; Haefeli WE
Antimicrob Agents Chemother; 2007 Jan; 51(1):239-44. PubMed ID: 17060517
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of concentration of voriconazole in aqueous humor after topical and oral administration in horses.
Clode AB; Davis JL; Salmon J; Michau TM; Gilger BC
Am J Vet Res; 2006 Feb; 67(2):296-301. PubMed ID: 16454636
[TBL] [Abstract][Full Text] [Related]
3. Aqueous and vitreous concentrations following topical administration of 1% voriconazole in humans.
Vemulakonda GA; Hariprasad SM; Mieler WF; Prince RA; Shah GK; Van Gelder RN
Arch Ophthalmol; 2008 Jan; 126(1):18-22. PubMed ID: 18195213
[TBL] [Abstract][Full Text] [Related]
4. Topical and oral voriconazole in the treatment of fungal keratitis.
Bunya VY; Hammersmith KM; Rapuano CJ; Ayres BD; Cohen EJ
Am J Ophthalmol; 2007 Jan; 143(1):151-3. PubMed ID: 17188052
[TBL] [Abstract][Full Text] [Related]
5. Comparison of voriconazole concentration in the aqueous humor and vitreous between non-scraped and scraped corneal epithelium groups after topical 1% voriconazole application.
Wei LC; Tsai TC; Tsai HY; Wang CY; Shen YC
Curr Eye Res; 2010 Jul; 35(7):573-9. PubMed ID: 20597643
[TBL] [Abstract][Full Text] [Related]
6. Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods.
Pascual A; Nieth V; Calandra T; Bille J; Bolay S; Decosterd LA; Buclin T; Majcherczyk PA; Sanglard D; Marchetti O
Antimicrob Agents Chemother; 2007 Jan; 51(1):137-43. PubMed ID: 17088483
[TBL] [Abstract][Full Text] [Related]
7. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans.
Hariprasad SM; Mieler WF; Holz ER; Gao H; Kim JE; Chi J; Prince RA
Arch Ophthalmol; 2004 Jan; 122(1):42-7. PubMed ID: 14718293
[TBL] [Abstract][Full Text] [Related]
8. Voriconazole -- better chances for patients with invasive mycoses.
Ghannoum MA; Kuhn DM
Eur J Med Res; 2002 May; 7(5):242-56. PubMed ID: 12069915
[TBL] [Abstract][Full Text] [Related]
9. Aqueous humor concentration of voriconazole after topical administration in rabbits.
Vorwerk CK; Streit F; Binder L; Tuchen S; Knop C; Behrens-Baumann W
Graefes Arch Clin Exp Ophthalmol; 2008 Aug; 246(8):1179-83. PubMed ID: 18491124
[TBL] [Abstract][Full Text] [Related]
10. Successful salvage treatment of Scedosporium apiospermum keratitis with topical voriconazole after failure of natamycin.
Al-Badriyeh D; Leung L; Davies GE; Stewart K; Kong D
Ann Pharmacother; 2009 Jun; 43(6):1139-42. PubMed ID: 19435962
[TBL] [Abstract][Full Text] [Related]
11. Corneal and aqueous humor concentrations of amphotericin B using three different routes of administration in a rabbit model.
Qu L; Li L; Xie H
Ophthalmic Res; 2010; 43(3):153-8. PubMed ID: 19887881
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of Fusarium keratitis with cornea transplantation and topical and systemic voriconazole.
Klont RR; Eggink CA; Rijs AJ; Wesseling P; Verweij PE
Clin Infect Dis; 2005 Jun; 40(12):e110-2. PubMed ID: 15909252
[TBL] [Abstract][Full Text] [Related]
13. Voriconazole and fungal keratitis: a report of two treatment failures.
Giaconi JA; Marangon FB; Miller D; Alfonso EC
J Ocul Pharmacol Ther; 2006 Dec; 22(6):437-9. PubMed ID: 17238810
[TBL] [Abstract][Full Text] [Related]
14. Successful use of topical voriconazole 1% alone as first-line antifungal therapy against Candida albicans keratitis.
Al-Badriyeh D; Leung L; Davies GE; Stewart K; Kong D
Ann Pharmacother; 2009 Dec; 43(12):2103-7. PubMed ID: 19861430
[TBL] [Abstract][Full Text] [Related]
15. Penetration of topical fluconazole into human aqueous humor.
Abbasoğlu OE; Hoşal BM; Sener B; Erdemoğlu N; Gürsel E
Exp Eye Res; 2001 Feb; 72(2):147-51. PubMed ID: 11161730
[TBL] [Abstract][Full Text] [Related]
16. Management of endogenous fungal endophthalmitis with voriconazole and caspofungin.
Breit SM; Hariprasad SM; Mieler WF; Shah GK; Mills MD; Grand MG
Am J Ophthalmol; 2005 Jan; 139(1):135-40. PubMed ID: 15652837
[TBL] [Abstract][Full Text] [Related]
17. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections.
Pascual A; Csajka C; Buclin T; Bolay S; Bille J; Calandra T; Marchetti O
Clin Infect Dis; 2012 Aug; 55(3):381-90. PubMed ID: 22610925
[TBL] [Abstract][Full Text] [Related]
18. Topical voriconazole as a novel treatment for fungal keratitis.
Sponsel W; Chen N; Dang D; Paris G; Graybill J; Najvar LK; Zhou L; Lam KW; Glickman R; Scribbick F
Antimicrob Agents Chemother; 2006 Jan; 50(1):262-8. PubMed ID: 16377696
[TBL] [Abstract][Full Text] [Related]
19. Penetration of voriconazole, 1%, eyedrops into human aqueous humor: a prospective open-label study.
Lau D; Fedinands M; Leung L; Fullinfaw R; Kong D; Davies G; Daniell M
Arch Ophthalmol; 2008 Mar; 126(3):343-6. PubMed ID: 18332313
[TBL] [Abstract][Full Text] [Related]
20. Random plasma concentrations of voriconazole decline over time.
Mulanovich V; Lewis RE; Raad II; Kontoyiannis DP
J Infect; 2007 Nov; 55(5):e129-30. PubMed ID: 17804077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
